microRNA-199a is able to reverse cisplatin resistance in human ovarian cancer cells through the inhibition of mammalian target of rapamycin

Oncology Letters

Volumn 6, Issue 3, 2013, Pages 789-794

  Wang, Zhongxian ^a   Ting, Zhou ^b   Li, Ya ^b   Chen, Gang ^b   Lu, Yunping ^b   Hao, Xing ^b  

^a CHINA THREE GORGES UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cisplatin resistance; Mammalian target of rapamycin; microRNA 199a; Ovarian cancer cells

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; CISPLATIN; MICRORNA; MICRORNA 199A; TARGET OF RAPAMYCIN KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CANCER; POLYMERASE CHAIN REACTION; PROTEIN SYNTHESIS REGULATION; REPORTER GENE; WESTERN BLOTTING;

EID: 84880404337     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1448     Document Type: Article

References (19)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. Wangpaichitr M, Wu C, You M, et al: Inhibition of mTOR restores cisplatin sensitivity through down-regulation of growth and anti-apoptotic proteins. Eur J Pharmacol 591: 124-127, 2008.
3. Nam EJ, Yoon H, Kim SW, et al: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
4. Torres A, Torres K, Maciejewski R and Harvey WH: MicroRNAs and their role in gynecological tumors. Med Res Rev 31: 895-923, 2010.
5. Cho WC: Updates in cancer research: insights from the AACR 100th Annual Meeting. Expert Rev Mol Diagn 9: 411-416, 2009.
6. Sorrentino A, Liu CG, Addario A, Peschle C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol 111: 478-486, 2008.
7. Fornari F, Milazzo M, Chieco P, et al: MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70: 5184-5193, 2010.
8. Hou J, Lin L, Zhou W, et al: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19: 232-243, 2011.
9. Castedo M, Ferri KF and Kroemer G: Mammalian target of rapamycin (mTOR): pro-and anti-apoptotic. Cell Death Differ 9: 99-100, 2002.
10. Castedo M, Roumier T, Blanco J, et al: Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope. EMBO J 21: 4070-4080, 2002.
11. Li X, Alafuzoff I, Soininen H, Winblad B and Pei JJ: Levels of mTOR and its downstream targets 4E-BP1, eEF2, and eEF2 kinase in relationships with tau in Alzheimer's disease brain. FEBS J 272: 4211-4220, 2005.
12. Zivny J, Klener P, Jr, Pytlik R and Andera L: The role of apoptosis in cancer development and treatment: focusing on the development and treatment of hematologic malignancies. Curr Pharm Des 16: 11-33, 2010.
13. Tsurutani J, West KA, Sayyah J, Gills JJ and Dennis PA: Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. Cancer Res 65: 8423-8432, 2005.
14. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW and Poon RT: Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 273: 201-209, 2009.
15. Mazzoletti M and Broggini M: PI3K/AKT/mTOR inhibitors in ovarian cancer. Curr Med Chem 17: 4433-4447, 2010.
16. Peng DJ, Wang J, Zhou JY and Wu GS: Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 394: 600-605, 2010.
17. Zhang HY, Zhang PN and Sun H: Aberration of the PI3K/AKT/mTOR signaling in epithelial ovarian cancer and its implication in cisplatin-based chemotherapy. Eur J Obstet Gynecol Reprod Biol 146: 81-86, 2009.
18. Foster H, Coley HM, Goumenou A, Pados G, Harvey A and Karteris E: Differential expression of mTOR signalling components in drug resistance in ovarian cancer. Anticancer Res 30: 3529-3534, 2010.
19. Wahid F, Shehzad A, Khan T and Kim YY: MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 1803: 1231-1243, 2010.